{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:01:46Z","timestamp":1783699306217,"version":"3.55.0"},"reference-count":35,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The\n            <jats:italic>in vitro<\/jats:italic>\n            activity of ceftazidime-avibactam and many comparator agents was determined against various resistant subsets of organisms selected among 36,380\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            and 7,868\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            isolates. The isolates were consecutively collected from 94 U.S. hospitals, and all isolates were tested for susceptibility by reference broth microdilution methods in a central monitoring laboratory (JMI Laboratories).\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            isolates resistant to carbapenems (CRE) and\/or ceftazidime-avibactam (MIC \u2265 16 \u03bcg\/ml) were evaluated for the presence of genes encoding extended-spectrum \u03b2-lactamases and carbapenemases. Ceftazidime-avibactam inhibited &gt;99.9% of all\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            at the susceptible breakpoint of \u22648 \u03bcg\/ml and was active against multidrug-resistant (MDR;\n            <jats:italic>n<\/jats:italic>\n            = 2,953; MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.25\/1 \u03bcg\/ml; 99.2% susceptible), extensively drug-resistant (XDR;\n            <jats:italic>n<\/jats:italic>\n            = 448; MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.5\/2 \u03bcg\/ml; 97.8% susceptible), and CRE (\n            <jats:italic>n<\/jats:italic>\n            = 513; MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.5\/2 \u03bcg\/ml; 97.5% susceptible) isolates. Only 82.2% of MDR\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            (\n            <jats:italic>n<\/jats:italic>\n            = 2,953) and 64.2% of ceftriaxone-nonsusceptible\n            <jats:named-content content-type=\"genus-species\">Klebsiella pneumoniae<\/jats:named-content>\n            (\n            <jats:italic>n<\/jats:italic>\n            = 1,063) isolates were meropenem susceptible. Among\n            <jats:named-content content-type=\"genus-species\">Enterobacter cloacae<\/jats:named-content>\n            (22.2% ceftazidime nonsusceptible), 99.8% of the isolates, including 99.3% of the ceftazidime-nonsusceptible isolates, were ceftazidime-avibactam susceptible. Only 23 of 36,380\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            (0.06%) isolates were ceftazidime-avibactam nonsusceptible, including 9 metallo-\u03b2-lactamase producers and 2 KPC-producing strains with porin alteration; the remaining 12 strains showed negative results for all \u03b2-lactamases tested. Ceftazidime-avibactam showed potent activity against\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 2\/4 \u03bcg\/ml; 97.1% susceptible), including MDR (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 4\/16 \u03bcg\/ml; 86.5% susceptible) isolates, and inhibited 71.8% of isolates nonsusceptible to meropenem, piperacillin-tazobactam, and ceftazidime (\n            <jats:italic>n<\/jats:italic>\n            = 628). In summary, ceftazidime-avibactam demonstrated potent activity against a large collection (\n            <jats:italic>n<\/jats:italic>\n            = 44,248) of contemporary Gram-negative bacilli isolated from U.S. patients, including organisms resistant to most currently available agents, such as CRE and meropenem-nonsusceptible\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            .\n          <\/jats:p>","DOI":"10.1128\/aac.01045-17","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T00:20:21Z","timestamp":1503361221000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":97,"title":["Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016"],"prefix":"10.1128","volume":"61","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Shortridge","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0291"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2171"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.11.025"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.007"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.174"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066615619895"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904124"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02083-16"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03514.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00540-16"},{"key":"e_1_3_2_13_2","first-page":"165","article-title":"Vital signs: carbapenem-resistant Enterobacteriaceae","volume":"62","author":"Jacob JT","year":"2013","unstructured":"Jacob JT KleinE LaxminarayanR BeldavsZ LynfieldR KallenAJ RicksP EdwardsJ SrinivasanA FridkinS RasheedKJ LonswayD BulensS HerreraR McDonaldLC PatelJ LimbagoB BellM CardoD. 2013. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep62:165\u2013170.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir202"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw239"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0725-1"},{"key":"e_1_3_2_18_2","unstructured":"Allergan\nUSA\n. 2016. Avycaz (ceftazidime-avibactam). Allergan USA Inc. Irvine CA USA. https:\/\/www.allergan.com\/assets\/pdf\/avycaz_pi."},{"key":"e_1_3_2_19_2","volume-title":"Zavicefta package insert","author":"AstraZeneca AB","year":"2016","unstructured":"AstraZeneca AB . 2016. Zavicefta package insert. AstraZeneca AB, Sodertalje, Sweden. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004027\/WC500210234.pdf."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00862-16"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis588"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12342"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05035-11"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.05.003"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx066"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/338782"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw480"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.11.005"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw378"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02429-13"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.03.032"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_2_33_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A10","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A10. 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_2_34_2","volume-title":"CLSI document M100-S27","author":"CLSI","year":"2017","unstructured":"CLSI. 2017. Performance standards for antimicrobial susceptibility testing: 27th informational supplement. CLSI document M100-S27. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_35_2","unstructured":"EUCAST. 2017. Breakpoint tables for interpretation of MICs and zone diameters (v7.0 January 2017). http:\/\/www.eucast.org\/clinical_breakpoints\/\n."},{"key":"e_1_3_2_36_2","volume-title":"Tygacil package insert","author":"Wyeth Pharmaceuticals","year":"2016","unstructured":"Wyeth Pharmaceuticals. 2016. Tygacil package insert. Wyeth Pharmaceuticals, Philadelphia, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01045-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01045-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:41:54Z","timestamp":1645476114000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01045-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1128\/AAC.01045-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01045-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"2017-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01045-17"}}